ImaRx Therapeutics, Inc. is a biopharmaceutical company with a research and development program focused on the development of new treatments for vascular disorders leveraging its proprietary microsphere and ultrasound or SonoLysis technology.

ImaRx Pharmaceutical Corp. , was founded in 1991 to develop diagnostic contrast agents for radiology. ImaRx Pharmaceutical Corp. conducted the early research and development work on 3 products that became FDA approved diagnostic contrast agents: LumenHance and SonoRx (licensed to Bracco) and Definity (licensed to DuPont and now owned by Lantheus Medical Imaging). ImaRx Pharmaceutical Corp, including the rights to Definity, was sold to Dupont in 1999. The company that became ImaRx Therapeutics, Inc. was formed during that transaction to retain the scientific team and all intellectual property outside the field of non-targeted ultrasound imaging. ImaRx's scientific team's early research and development of ultrasound contrast agents provided the foundation for its microbubble technology that is the basis for its SonoLysis program. Today, ImaRx Therapeutics is focused on developing therapies for stroke and other vascular disorders using its proprietary microbubble technology to treat occlusions and the resulting ischemia.